RESOURCES

Innovative Mouse Models to Accelerate the Development of In Vivo CAR-T Therapies

How do we accurately predict the clinical success of in vivo CAR-T therapies before they reach patients? In this webinar, we’ll explore our next-generation mouse models that are transforming preclinical assessment. We'll delve into cutting-edge strategies for developing CAR-T therapies directly in the body using innovative methods like mRNA/LNP delivery and viral vectors, and discuss why choosing the right models, (ranging from immunodeficient xenografts to advanced humanized strains like NCG, PBMC-NCG, and HSC-NCG), are pivotal in bridging preclinical research to clinical success, enabling precise evaluation of tumor clearance, CAR persistence, cytokine responses and safety.

Advancing Respiratory Disease Drug Development: A Comprehensive Mouse Platform for Translational Research

Respiratory diseases encompass infectious lung diseases, airway diseases, and parenchymal diseases. In recent years, research and development for novel therapeutics to treat these diseases have seen several exciting breakthroughs, and genetically engineered mouse models continue to stand out as an invaluable tool for evaluating those novel drugs.

Expanding Indications for GLP-1 Receptor Targeted Therapies in Mouse Models of Metabolic Disease

While drug development continues to diversify, current obesity treatments are challenged by high rates of therapy discontinuation, weight regain, and lean mass loss, underscoring the limitations of available options. Moreover, obesity often presents with multiple comorbidities such as metabolic dysfunction-associated steatohepatitis (MASH) and cardiovascular diseases, highlighting the need for personalized treatment strategies.

Immature neutrophils promote tumor growth and metastasis through immune suppression

Neutrophils, long recognized as first responders in the immune system, are now emerging as critical players in cancer progression. Recent findings reveal that immature neutrophils not only accumulate in primary and metastatic tumors but also actively suppress anti-tumor immunity, undermining the efficacy of immunotherapies.

Overcoming Challenges in the Post-PD-1 Era of Cancer Immunotherapy

Immune checkpoint inhibitors targeting PD-1 have revolutionized cancer treatment, offering durable responses in a subset of patients. However, as clinical use expands, so do the challenges, with primary and acquired resistance remaining major barriers to broader efficacy. While anti-PD1 monotherapy was initially approved for patients with high PD-L1 expression, the current landscape has shifted toward combination strategies that aim to enhance immune activation and circumvent resistance mechanisms.

Unlock the Potential of Preclinical ALS Research with Advanced Mouse Models

Amyotrophic Lateral Sclerosis (ALS) remains one of the most challenging neurodegenerative diseases to study and treat, with limited therapeutic options available for patients. To bridge the gap between basic research and clinical treatment, robust, reliable, and translational animal models are essential.

Knockout All Project (KOAP): Genetically Modified Mouse Models and their Applications

Join us for an exclusive webinar exploring GemPharmatech’s ambitious Knockout All Project (KOAP), a large-scale initiative to systematically generate knockout (KO) and conditional knockout (cKO) mouse strains for all ~23,000 protein coding genes in the mouse genome.

Murine Models for Heart Failure Research

Heart failure (HF), a leading global cause of mortality, affects over 64 million people worldwide, with rising prevalence driven by aging populations and increasing comorbidities. Based on left ventricular ejection fraction (LVEF), HF is classified into two primary subtypes: HF with reduced ejection fraction (HFrEF; LVEF <40%), which is characterized by impaired systolic contraction, frequently secondary to ischemic injury; and HF with preserved ejection fraction (HFpEF; LVEF ≥50%), which is defined by diastolic dysfunction with ventricular stiffness, predominantly linked to hypertension, metabolic disorders, and aging.
Hypertrophic cardiomyopathy (HCM), a genetic disorder causing pathological left ventricular hypertrophy and diastolic impairment, represents a significant etiological contributor to both HF subtypes, particularly HFpEF.
In this webinar, GemPharmatech’s Dr. Qi Xiao will introduce diverse preclinical models developed for different applications in acceleration of therapeutic discovery.

Preclinical Strategies to Evaluate T-Cell Engagers